August 2026
1. PANDEY A, Patel KV
   Pharmacotherapy for Management of Type 2 Diabetes and CKM Syndrome: SGLT2 Inhibitors and GLP-1-Based Therapies for All vs a Risk-Based Approach?
   J Am Coll Cardiol. 2026;88:559-562.
   

   >> Share

   
   June 2026
2. KAUL U, Sinha SK, Singh R, Parida AK, et al
   Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.
   J Am Coll Cardiol. 2026 Jun 24:S0735-1097(26)06637.
   

   >> Share

   
   
3. GONG J, Chiu N, Clinch KA, Qian Y, et al
   Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.
   J Am Coll Cardiol. 2026 Jun 17:S0735-1097(26)06350.
   

   >> Share

   
   
4. TUTTLE KR, Bakris GL, Baeres FMM, Bang CN, et al
   Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
   J Am Coll Cardiol. 2026;87:2996-3012.
   

   >> Share

   
   May 2026
5. SASEEN JJ, Soffer DE, Wilkins JT
   New Dyslipidemia Guideline Expands Treatment Options and Risk Assessment in Patients With Diabetes and Chronic Kidney Disease.
   J Am Coll Cardiol. 2026;87:2573-2575.
   

   >> Share

   
   April 2026
6. FIORETTI F, Petrie MC, Dickert NW, Butler J, et al
   Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.
   J Am Coll Cardiol. 2026;87:2034-2043.
   

   >> Share

   
   
7. BU F, Wu R, Ostropolets A, Aminorroaya A, et al
   Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
   J Am Coll Cardiol. 2026 Apr 3:S0735-1097(26)05724.
   

   >> Share

   
   March 2026
8. VADUGANATHAN M, Green JB, Heerspink HJL, Mann JFE, et al
   Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial.
   J Am Coll Cardiol. 2026 Mar 24:S0735-1097(26)05495.
   

   >> Share

   
   
9. CAVENDER MA, Marx N, Mulvagh SL, Deanfield JE, et al
   Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease.
   J Am Coll Cardiol. 2026;87:1369-1373.
   

   >> Share

   
   February 2026
10. AGARWAL R, Green JB, Heerspink HJL, McGill JB, et al
    Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
    J Am Coll Cardiol. 2026;87:772-784.
    

    >> Share

    
    January 2026
11. VERDECCHIA P, Angeli F, Reboldi G
    The Relation Between Blood Pressure and Outcomes in Diabetes: With or Without the J Curve?
    J Am Coll Cardiol. 2026 Jan 28:S0735-1097(25)10423.
    

    >> Share

    
    
12. WANG S, Wang K, Gu H, Zhang J, et al
    Blood Pressure Levels and Outcomes in Type 2 Diabetes: Dose-Response Meta-Analysis of 5.87 Million Cohort Participants.
    J Am Coll Cardiol. 2026 Jan 14:S0735-1097(25)10148.
    

    >> Share

    
    December 2025
13. DAS SR, Bonaca MP, Creager MA, Maruthur N, et al
    Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.
    J Am Coll Cardiol. 2025 Dec 17:S0735-1097(25)10282.
    

    >> Share

    
    November 2025
14. LEE HH, Crawford EB, Cho SMJ, Krawisz AK, et al
    Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
    J Am Coll Cardiol. 2025 Nov 26:S0735-1097(25)09917.
    

    >> Share

    
    
15. VERMA S, Catarig AM, Houlind K, Ludvik B, et al
    Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
    J Am Coll Cardiol. 2025;86:1843-1857.
    

    >> Share

    
    
16. OSTROMINSKI JW, Neuen BL, Claggett BL, Filippatos G, et al
    Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes.
    J Am Coll Cardiol. 2025 Nov 18:S0735-1097(25)10071.
    

    >> Share

    
    September 2025
17. PACKER M, Lam CSP, Butler J, Zannad F, et al
    Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
    J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07341.
    

    >> Share

    
    
18. KRUMHOLZ HM, Inzucchi SE
    Beyond Adiposity: Embracing Complexity in Diabetes-Associated HFpEF.
    J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07385.
    

    >> Share

    
    
19. KANG D, Choi KH, Kim JH
    Statins in Type 1 Diabetes: Bridging the Evidence Gap With Target Trial Emulation.
    J Am Coll Cardiol. 2025;86:810-812.
    

    >> Share

    
    
20. BLAIS JE, Yan VKC, Chan EWY, Wong ICK, et al
    Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
    J Am Coll Cardiol. 2025;86:797-809.
    

    >> Share

    
    
21. PACKER M, Zile MR, Kramer CM, DiMaria JM, et al
    Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
    J Am Coll Cardiol. 2025;86:696-707.
    

    >> Share

    
    August 2025
22. GALLI M, Benenati S, Laudani C, Simeone B, et al
    Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07492.
    

    >> Share

    
    May 2025
23. AMINORROAYA A, Oikonomou EK, Biswas D, Jastreboff AM, et al
    Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.
    J Am Coll Cardiol. 2025;85:1858-1872.
    

    >> Share

    
    
24. HO JE, Chen ZZ, Lau ES
    Insulin Resistance and Diabetes in HFpEF: Bystander or Instigator?
    J Am Coll Cardiol. 2025;85:1789-1791.
    

    >> Share

    
    
25. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
    Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025;85:1774-1788.
    

    >> Share

    
    April 2025
26. BORROWMAN JD, Huang X, Petito LC, Perak AM, et al
    Prepregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife.
    J Am Coll Cardiol. 2025;85:1536-1546.
    

    >> Share

    
    December 2024
27. SPERLING LS
    The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?
    J Am Coll Cardiol. 2024;84:2260-2263.
    

    >> Share

    
    
28. GYLDENKERNE C, Kahlert J, Thrane PG, Olesen KKW, et al
    2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study.
    J Am Coll Cardiol. 2024;84:2251-2259.
    

    >> Share

    
    November 2024
29. SANTOS-PARDO I, Andersson Franko M, Nystrom T
    Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e321.
    

    >> Share

    
    
30. LIU C, Li X, Cong H
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e319-e320.
    

    >> Share

    
    
31. WARRAICH HJ, Patrick-Lake B, Saha A, Rashid L, et al
    Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration.
    J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028.
    

    >> Share

    
    
32. PATEL KV, Chunawala Z, Verma S, Segar MW, et al
    Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study.
    J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10417.
    

    >> Share

    
    September 2024
33. MENTZ RJ, Kittipibul V
    Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle.
    J Am Coll Cardiol. 2024;84:1089-1091.
    

    >> Share

    
    
34. BHATT AS, Bhatt DL, Steg PG, Szarek M, et al
    Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    J Am Coll Cardiol. 2024;84:1078-1088.
    

    >> Share

    
    
35. EVERETT BM, Wexler DJ
    Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease.
    J Am Coll Cardiol. 2024;84:918-920.
    

    >> Share

    
    
36. KHERA R, Aminorroaya A, Dhingra LS, Thangaraj PM, et al
    Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    J Am Coll Cardiol. 2024;84:904-917.
    

    >> Share

    
    August 2024
37. MANUBOLU VS, Lakshmanan S, Kinninger A, Ahmad K, et al
    Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
    J Am Coll Cardiol. 2024;84:865-867.
    

    >> Share

    
    
38. NEUEN BL, Ostrominski JW, Claggett B, Beldhuis IE, et al
    Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08155.
    

    >> Share

    
    
39. PRATLEY RE, Tuttle KR, Rossing P, Rasmussen S, et al
    Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
    J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116.
    

    >> Share

    
    
40. NEUEN BL, Solomon SD
    Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:709-711.
    

    >> Share

    
    
41. EDMONSTON D, Mulder H, Lydon E, Chiswell K, et al
    Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:696-708.
    

    >> Share

    
    
42. SHIN JI, Xu Y, Chang AR, Carrero JJ, et al
    Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    J Am Coll Cardiol. 2024;84:683-693.
    

    >> Share

    
    
43. OSTROMINSKI JW, Jemma Cho SM, Vaduganathan M, Honigberg MC, et al
    Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747.
    

    >> Share

    
    
44. INZUCCHI SE, Arai AE
    Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    J Am Coll Cardiol. 2024;84:558-560.
    

    >> Share

    
    
45. CHOWDHARY A, Thirunavukarasu S, Joseph T, Jex N, et al
    Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:540-557.
    

    >> Share

    
    July 2024
46. MARINHO LL, Everett BM, Aday AW, Visseren FLJ, et al
    Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.
    J Am Coll Cardiol. 2024;84:408-410.
    

    >> Share

    
    
47. BABER U
    Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?
    J Am Coll Cardiol. 2024;84:273-275.
    

    >> Share

    
    
48. GUGLIN M, Hillerson D
    Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities.
    J Am Coll Cardiol. 2024;84:244-246.
    

    >> Share

    
    
49. LOPEZ J, Liu Y, Butler J, Del Prato S, et al
    Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.
    J Am Coll Cardiol. 2024;84:233-243.
    

    >> Share

    
    June 2024
50. VERMA S, Butler J, Borlaug BA, Davies M, et al
    Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
    J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445.
    

    >> Share

    
    
51. PINNEY SP, Costanzo MR
    As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
    J Am Coll Cardiol. 2024;83:2423-2425.
    

    >> Share

    
    
52. LALA A, Mentz RJ, Santos-Gallego CG
    The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
    J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407.
    

    >> Share

    
    May 2024
53. SANTOS-PARDO I, Andersson Franko M, Lagerqvist B, Ritsinger V, et al
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06933.
    

    >> Share

    
    April 2024
54. BONACA MP, Bhatt DL, Simon T, Fox KM, et al
    Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
    J Am Coll Cardiol. 2024;83:1627-1636.
    

    >> Share

    
    
55. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    

    >> Share

    
    
56. WONG ND, Fan W, Hu X, Ballantyne C, et al
    Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    J Am Coll Cardiol. 2024;83:1511-1525.
    

    >> Share

    
    
57. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    

    >> Share

    
    
58. PACKER M
    SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
    J Am Coll Cardiol. 2024;83:1399-1402.
    

    >> Share

    
    
59. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    

    >> Share

    
    
60. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    

    >> Share

    
    
61. COSTANZO MR, Januzzi JL
    Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    J Am Coll Cardiol. 2024;83:1307-1309.
    

    >> Share

    
    
62. JANUZZI JL JR, Butler J, Del Prato S, Ezekowitz JA, et al
    Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613.
    

    >> Share

    
    March 2024
63. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e89.
    

    >> Share

    
    
64. OHSHIRO Y
    Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e87.
    

    >> Share

    
    
65. HANSEN MK, Olesen KKW, Gyldenkerne C, Thrane PG, et al
    Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    J Am Coll Cardiol. 2024;83:956-958.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share